# PREOPANC-3

Source: https://onco.cc/trials/preopanc-3/  
OnCo record `preopanc-3` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PREOPANC-3 is the European twin of Alliance A021806: the same modified FOLFIRINOX given either around surgery or only afterwards for operable pancreatic cancer. Recruitment of 378 patients has closed and the first results are expected after the January 2027 primary completion date.

## Summary

PREOPANC-3 (protocol in BMC Cancer 2023) randomises patients with resectable pancreatic cancer to perioperative or adjuvant modified FOLFIRINOX with overall survival as the primary endpoint; ClinicalTrials.gov on 24 September 2026 lists it as active but no longer recruiting, 378 participants (estimated), started 7 September 2021, primary completion January 2027 and completion July 2029, at sites in the Netherlands and Sweden. It follows PREOPANC-1 (neoadjuvant chemoradiotherapy beat upfront surgery at five years) and PREOPANC-2 (neoadjuvant FOLFIRINOX equal to neoadjuvant chemoradiotherapy), and with A021806 it will answer the surgery-first question that NORPACT-1 answered against neoadjuvant treatment in a smaller Nordic trial.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: PREOPANC 3
- Registry id: NCT04927780
- Phase: 3
- Setting: Resectable pancreatic ductal adenocarcinoma in the Netherlands and Sweden: perioperative modified FOLFIRINOX (eight cycles before surgery, four after) against upfront surgery and twelve adjuvant cycles, with overall survival as the primary endpoint
- Sponsor: Erasmus Medical Center, Dutch Pancreatic Cancer Group and Dutch Cancer Society
- Enrolled: 378

## Sources

- ClinicalTrials.gov NCT04927780: https://clinicaltrials.gov/study/NCT04927780
- PREOPANC-3 protocol (BMC Cancer 2023): https://doi.org/10.1186/s12885-023-11141-5

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/)
- institutions: [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/)
- terms: [Neoadjuvant / adjuvant / perioperative](https://onco.cc/terms/neoadjuvant-adjuvant/), [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)
- trials: [Alliance A021806](https://onco.cc/trials/alliance-a021806/), [NORPACT-1](https://onco.cc/trials/norpact-1/), [PREOPANC-1](https://onco.cc/trials/preopanc/), [PREOPANC-2](https://onco.cc/trials/preopanc-2/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/)

---
JSON: https://onco.cc/api/v1/entities/preopanc-3.json